CORDIS · 101136656 · HORIZON
HyPowerGT DEMONSTRATING A HYDROGEN-POWERED GAS-TURBINE ENGINE FUELLED WITH UP TO 100% H2 – (HYPOWERGT)
Coordinator: SINTEF ENERGI AS (NO)
The HyPowerGT project aims at moving technological frontiers to enable gas turbines to operate on hydrogen without dilution. The core technology is a novel dry-low emission combustion technology (DLE H2) capable of handling mixtures of natural gas and hydrogen with concentrations up to 100% H2. The combustion technology has been successfully validated at TRL5 (early 2021) retrofitted on the combustion system of a 13 MWe industrial gas turbine (NovaLT12). Besides ensuring low emissions and high efficiency, the DLE H2 combustion technology offers fuel flexibility and response capability on a pa…
About Horizon Europe (2021–2027)
Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.
Co-funding: the European Union contributes €6.0M toward a total project budget of €12.3M — a funding rate of 49%, with the remainder covered by the consortium partners. The project runs over approximately 4 years from 2024-01-01 to 2027-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from NO
see all →- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · H2020 · €100.0M
- CHIKVAX_CHIM — Late-stage clinical development of Chikungunya vaccines in endemic countries (CHIKV) and Controlled Human Infection Models for SARS-CoV2 and other beta coronaviruses (CHIM).101126531 · HORIZON · €70.0M
- ECRC — Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola857934 · H2020 · €36.0M
- FILOVAX — Development of Broadly Protective Filovirus Vaccines101167138 · HORIZON · €35.0M
- RIFTVAX — Clinical development of Rift Valley fever vaccines in endemic regions101081290 · HORIZON · €35.0M
- REFHYNE II — Clean Refinery Hydrogen for Europe II101036970 · H2020 · €32.4M
Other HORIZON projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon Europe through a joint programme of the members of the EUROfusion consortium101052200 · DE · €549.4M
- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · ES · €206.9M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · FR · €200.0M
- EIT RM BP23-25 — EIT RawMatrials Business Plan 2023-2025101113034 · DE · €155.5M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · BE · €153.0M
- EIT HEI — EIT Higher Education Initiative - Scaling Europe’s Innovation Ecosystems101270329 · DE · €130.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-JU-IA funding scheme.
- What is the EU contribution?
- The European Commission contributes €6.0M toward a total project budget of €12.3M.
- Which EU programme funds it?
- The project is funded under Horizon Europe (2021–2027), call HORIZON-JTI-CLEANH2-2023-1.
- Who coordinates the project?
- The project is coordinated by SINTEF ENERGI AS (NO).
- What is the project timeline?
- The project runs from 2024-01-01 to 2027-12-31 — approximately 4 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101136656.